Evaluation of immunomodulatory effects of lamotrigine in BALB/c mice

1. Food and Drug Administration, Center for Drug Evaluation and Research, U.S. Department of Health and Human Services, Guidance for Industry: Immunotoxicology Evaluation of Investigational New Drugs, October 2002; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079239.pdf; last access date July 9, 2017.Search in Google Scholar

2. International Conference on Harmonisation, Harmonised Tripartite Guideline: Immunotoxicity Studies for Human Pharmaceuticals S8, May 2005; http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002851.pdf; last access date July 9, 2017.Search in Google Scholar

3. M. Collinge, L. A. Burns-Naas, G. J. Chellman, T. T. Kawabata, W. J. Komocsar, J. R. Piccotti, J. Shenton and D. Wierda, Developmental immunotoxicity (DIT) testing of pharmaceuticals: current practices, state of the science, knowledge gaps, and recommendations, J. Immunotoxicol. 9 (2012) 210-230; https://doi.org/10.3109/1547691X.2012.66148610.3109/1547691X.2012.661486Search in Google Scholar

4. B. Blaszczyk, W. Lason and S. J. Czuczwar, Antiepileptic drugs and adverse skin reactions: An update, Pharmacol. Rep. 67 (2015) 426-434; https://doi.org/10.1016/j.pharep.2014.11.00910.1016/j.pharep.2014.11.009Search in Google Scholar

5. T. Shimada, T. Takemiya, H. Sugiura and K. Yamagata, Role of inflammatory mediators in the pathogenesis of epilepsy, Mediators Inflam. 2014 (2014), Article 901902 (8 pages); https://doi.org/10.1155/2014/90190210.1155/2014/901902Search in Google Scholar

6. E. E. de Vries, B. van den Munckhof, K. P. Braun, A. van Royen-Kerkhof, W. de Jager and F. E. Jansen, Inflammatory mediators in human epilepsy: A systematic review and meta-analysis, Neurosci. Biobehav. Rev. 63 (2016) 177-190; https://doi.org/10.1016/j.neubiorev.2016.02.00710.1016/j.neubiorev.2016.02.007Search in Google Scholar

7. J. T. Jarvela, F. R. Lopez-Picon, A. Plysjuk, S. Ruohonen and I. E. Holopainen, Temporal profiles of age-dependent changes in cytokine mRNA expression and glial cell activation after status epilepticus in postnatal rat hippocampus, J. Neuroinflammation 8 (2011), Article 29 (12 pages); https://doi.org/10.1186/1742-2094-8-2910.1186/1742-2094-8-29Search in Google Scholar

8. R. Pacifici, L. Paris, S. Di Carlo, A. Bacosi, S. Pichini and P. Zuccaro, Cytokine production in blood mononuclear cells from epileptic patients, Epilepsia 36 (1995) 384-387.10.1111/j.1528-1157.1995.tb01013.xSearch in Google Scholar

9. G. De Sarro, D. Rotiroti, M.G. Audino, S. Gratteri and G. Nistico, Effects of interleukin-2 on various models of experimental epilepsy in DBA/2 mice, Neuroimmunomodulation 1 (1994) 361-369.10.1159/000097189Search in Google Scholar

10. N. Basaran, F. Hincal, E. Kansu and A. Ciger, Humoral and cellular immune parameters in untreated and phenytoin-or carbamazepine-treated epileptic patients, Int. J. Immunopharmacol. 16 (1994) 1071-1077.10.1016/0192-0561(94)90087-6Search in Google Scholar

11. A. Basta-Kaim, B. Budziszewska, M. Leskiewicz, M. Kubera, G. Jagla, W. Nowak, S. J. Czuczwar and W. Lason, Effects of new antiepileptic drugs and progabide on the mitogen-induced proliferative activity of mouse splenocytes, Pharmacol. Rep. 60 (2008) 925-932.Search in Google Scholar

12. H. Himmerich, S. Bartsch, H. Hamer, R. Mergl, J. Schonherr, C. Petersein, A. Munzer, K. C. Kirkby, K. Bauer and U. Sack, Impact of mood stabilizers and antiepileptic drugs on cytokine production in-vitro, J. Psychiatr. Res. 47 (2013) 1751-1759; https://doi.org/10.1016/j.jpsychires.2013.07.02610.1016/j.jpsychires.2013.07.02623978396Search in Google Scholar

13. H. Himmerich, S. Bartsch, H. Hamer, R. Mergl, J. Schonherr, C. Petersein, A. Munzer, K. C. Kirkby, K. Bauer and U. Sack, Modulation of cytokine production by drugs with antiepileptic or mood stabilizer properties in anti-CD3- and anti-Cd40-stimulated blood in vitro, Oxid. Med. Cell Longev. 2014 (2014) article 806162 (11 pages); https://doi.org/10.1155/2014/80616210.1155/2014/806162397677324757498Search in Google Scholar

14. K. S. Prabhavalkar, N. B. Poovanpallil and L. K. Bhatt, Management of bipolar depression with lamotrigine: an antiepileptic mood stabilizer, Front. Pharmacol. 6 (2015) article 242 (11 pages); https://doi.org/10.3389/fphar.2015.0024210.3389/fphar.2015.00242461593626557090Search in Google Scholar

15. X. Q. Wang, B. Lv, H. F. Wang, X. Zhang, S. Y. Yu, X. S. Huang, J. T. Zhang, C. L. Tian and S. Y. Lang, Lamotrigine induced DIHS/DRESS: Manifestations, treatment, and outcome in 57 patients, Clin. Neurol. Neurosurg. 138 (2015) 1-7; https://doi.org/10.1016/j.clineuro.2015.07.00810.1016/j.clineuro.2015.07.00826209753Search in Google Scholar

16. S. Svalheim, U. Mushtaq, M. Mochol, G. Luef, M. Rauchenzauner, S. S. Froland and E. Tauboll, Reduced immunoglobulin levels in epilepsy patients treated with levetiracetam, lamotrigine, or carbamazepine, Acta Neurol. Scand. 127 (2013) 11-15; https://doi.org/10.1111/ane.1204410.1111/ane.1204423190286Search in Google Scholar

17. M. Fararjeh, M. K. Mohammad, Y. Bustanji, H. Alkhatib and S. Abdalla, Evaluation of immunosuppression induced by metronidazole in Balb/c mice and human peripheral blood lymphocytes, Int. Immunopharmacol. 8 (2008) 341-350; https://doi.org/10.1016/j.intimp.2007.10.01810.1016/j.intimp.2007.10.01818182250Search in Google Scholar

18. E. K. St Louis, Monitoring antiepileptic drugs: a level-headed approach, Curr. Neuropharmacol. 7 (2009) 115-119; https://doi.org/10.2174/15701590978884893810.2174/157015909788848938273000219949569Search in Google Scholar

19. E. Y. Abu-Rish, V. Kasabri, M. M. Hudaib, S. H. Mashalla, L. H. Al Alawi, K. Tawaha, M. K. Mohammad, Y. S. Mohamed and Y. Bustanji, Evaluation of antiproliferative activity of some traditional anticancer herbal remedies from Jordan, Trop. J. Pharm. Res. 15 (2016) 469-474; https://doi.org/10.4314/tjpr.v15i3.610.4314/tjpr.v15i3.6Search in Google Scholar

20. G. Sachs, C. Bowden, J. R. Calabrese, T. Ketter, T. Thompson, R. White and B. Bentley, Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder, Bipolar Disord. 8 (2006) 175-181; https://doi.org/10.1111/j.1399-5618.2006.00308.x10.1111/j.1399-5618.2006.00308.x16542188Search in Google Scholar

21. M. F. Cesta, Normal structure, function, and histology of the spleen, Toxicol. Pathol. 34 (2006) 455-465; https://doi.org/10.1080/0192623060086774310.1080/0192623060086774317067939Search in Google Scholar

22. H. Tryphonas, Approaches to detecting immunotoxic effects of environmental contaminants in humans, Environ. Health Perspect. 109 (2001) 877-884.Search in Google Scholar

23. R. Schrijvers, L. Gilissen, A. M. Chiriac and P. Demoly, Pathogenesis and diagnosis of delayedtype drug hypersensitivity reactions, from bedside to bench and back, Clin. Transl. Allergy 5 (2015) article 31 (10 pages); https://doi.org/10.1186/s13601-015-0073-810.1186/s13601-015-0073-8455872626339470Search in Google Scholar

24. M. C. Garcia-Pelayo, V. S. Bachy, D. A. Kaveh and P. J. Hogarth, BALB/c mice display more enhanced BCG vaccine induced Th1 and Th17 response than C57BL/6 mice but have equivalent protection, Tuberculosis (Edinburgh) 95 (2015) 48-53; https://doi.org/10.1016/j.tube.2014.10.01210.1016/j.tube.2014.10.01225467292Search in Google Scholar

25. E. Kay, L. Gomez-Garcia, A. Woodfin, R. S. Scotland and J. R. Whiteford, Sexual dimorphisms in leukocyte trafficking in a mouse peritonitis model, J. Leukoc. Biol. 98 (2015) 805-817; https://doi.org/10.1189/jlb.3A1214-601RR10.1189/jlb.3A1214-601RR26138922Search in Google Scholar

26. D. J. Naisbitt, J. Farrell, G. Wong, J. P. Depta, C. C. Dodd, J. E. Hopkins, C. A. Gibney, D. W. Chadwick, W. J. Pichler, M. Pirmohamed and B. K. Park, Characterization of drug-specific T cells in lamotrigine hypersensitivity, J. Allergy Clin. Immunol. 111 (2003) 1393-1403.10.1067/mai.2003.150712789244Search in Google Scholar

27. E. Beghi and S. Shorvon, Antiepileptic drugs and the immune system, Epilepsia 52 (2011) 40-44; https://doi.org/10.1111/j.1528-1167.2011.03035.x10.1111/j.1528-1167.2011.03035.x21542845Search in Google Scholar

28. J. M. Dwyer and C. Johnson, The use of concanavalin A to study the immunoregulation of human T cells, Clin. Exp. Immunol. 46 (1981) 237-249.Search in Google Scholar

29. A. L. Rodríguez-Perea, E. D. Arcia, C. M. Rueda and P. A. Velilla, Phenotypical characterization of regulatory T cells in humans and rodents, Clin. Exp. Immunol. 185 (2016) 281-291; https://doi.org/10.1111/cei.1280410.1111/cei.12804499152327124481Search in Google Scholar

30. J. A. Bellanti, Immunology IV: Clinical Applications in Health and Disease, 3rd ed., I Care Press, Bethesda (MD) 2012.Search in Google Scholar

31. S. Liimatainen, M. Fallah, E. Kharazmi, A. M. Haapala, J. Isojarvi and J. Peltola, High concentration of immunoglobulin A is associated with temporal lobe epilepsy, Epilepsy Res. 103 (2013) 54-61; https://doi.org/10.1016/j.eplepsyres.2012.06.00210.1016/j.eplepsyres.2012.06.00222749917Search in Google Scholar